

# Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	1.5	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	3	6.0	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.3	nc	(nc-nc)
Male	6	2.1	290.9	(106.2-633.1)	<b><u>Ovary</u></b>				
Female	1	1.7	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	8	6.5	123.5	(53.2-243.4)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.1	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.4	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	0.5	nc	(nc-nc)	Male	32	22.4	143.1	(97.8-202.0)
Female	0	0.1	nc	(nc-nc)	Female	16	19.6	81.4	(46.5-132.3)
<b><u>Lung and Bronchus</u></b>									
Male	6	2.9	205.5	(75.0-447.2)					
Female	1	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	5.6	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	5	3.3	153.2	(49.4-357.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	23	22.5	102.2	(64.8-153.4)	Female	3	2.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.0	nc	(nc-nc)
Male	9	7.7	117.0	(53.4-222.0)	<b><u>Ovary</u></b>				
Female	11	6.3	174.4	(86.9-312.1)	Female	4	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	1.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	23	22.4	102.6	(65.0-153.9)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.4	nc	(nc-nc)
Male	5	3.3	150.0	(48.4-350.2)	Female	0	0.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.1	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	4.6	217.4	(104.1-399.8)
Male	0	2.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.5	nc	(nc-nc)	Female	1	4.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	74	81.5	90.8	(71.3-114.1)
Female	0	0.5	nc	(nc-nc)	Female	77	73.4	104.9	(82.8-131.2)
<b><u>Lung and Bronchus</u></b>									
Male	9	10.4	86.8	(39.6-164.8)					
Female	8	9.1	88.2	(38.0-173.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	47	42.9	109.5	(80.5-145.6)	Male	24	27.1	88.7	(56.8-131.9)
Female	24	17.5	137.4	(88.0-204.4)	Female	16	23.8	67.2	(38.4-109.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	8.4	59.7	(19.2-139.3)	Male	2	6.8	nc	(nc-nc)
Female	3	7.5	nc	(nc-nc)	Female	4	5.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	28	23.6	118.7	(78.8-171.5)
Female	171	168.5	101.5	(86.9-117.9)	Female	21	22.2	94.6	(58.5-144.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	10	7.1	141.1	(67.5-259.4)	Male	15	16.1	93.1	(52.0-153.5)
<b><u>Colon / Rectum</u></b>					Female	8	8.4	95.8	(41.2-188.8)
Male	52	54.1	96.2	(71.8-126.1)	<b><u>Ovary</u></b>				
Female	70	59.0	118.6	(92.4-149.8)	Female	17	16.6	102.6	(59.7-164.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	11.1	99.4	(49.5-177.8)	Male	13	13.4	97.0	(51.6-165.9)
Female	5	3.4	147.1	(47.4-343.4)	Female	21	15.6	134.8	(83.4-206.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	4.0	nc	(nc-nc)	Male	137	156.7	87.4	(73.4-103.4)
Female	4	3.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	16	10.3	156.0	(89.1-253.4)
Male	24	21.8	110.1	(70.5-163.8)	Female	7	6.7	105.1	(42.1-216.5)
Female	12	14.0	85.5	(44.1-149.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	6.5	nc	(nc-nc)
Male	10	6.3	157.9	(75.6-290.4)	<b><u>Thyroid</u></b>				
Female	3	1.9	nc	(nc-nc)	Male	14	8.2	170.0	(92.8-285.2)
<b><u>Leukemia</u></b>					Female	30	28.7	104.5	(70.5-149.2)
Male	25	15.1	165.6	(107.1-244.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	12.5	80.1	(38.3-147.3)	Female	34	37.6	90.3	(62.6-126.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	11.1	62.8	(25.2-129.5)	Male	607	566.9	107.1	(98.7-115.9)
Female	3	4.3	nc	(nc-nc)	Female	617	597.9	103.2	(95.2-111.7)
<b><u>Lung and Bronchus</u></b>									
Male	108	78.3	137.9	(113.1-166.5)					
Female	86	84.9	101.3	(81.0-125.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	8.6	197.1	(114.8-315.6)	Male	7	5.8	119.9	(48.0-247.0)
Female	4	3.0	nc	(nc-nc)	Female	5	4.4	112.7	(36.3-263.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	5	5.0	99.6	(32.1-232.5)
Female	37	33.0	112.1	(79.0-154.6)	Female	7	4.0	177.1	(71.0-365.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.6	nc	(nc-nc)
Male	11	11.3	97.0	(48.4-173.6)	<b><u>Ovary</u></b>				
Female	14	10.0	140.2	(76.6-235.2)	Female	0	3.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.4	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	30	35.2	85.3	(57.6-121.8)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.1	nc	(nc-nc)
Male	11	4.8	227.5	(113.4-407.0)	Female	4	1.1	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.3	nc	(nc-nc)
Male	6	1.4	424.3	(154.9-923.6)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	5.7	nc	(nc-nc)
Male	0	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.2	nc	(nc-nc)	Female	12	7.6	157.2	(81.2-274.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	134	121.5	110.3	(92.4-130.7)
Female	2	0.8	nc	(nc-nc)	Female	140	110.7	126.4	(106.4-149.2)
<b><u>Lung and Bronchus</u></b>									
Male	16	16.2	98.9	(56.5-160.5)					
Female	29	15.3	189.1	(126.6-271.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	3.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	5.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.6	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	7	19.2	36.4	(14.6-75.0)
Female	0	0.1	nc	(nc-nc)	Female	7	11.9	59.0	(23.6-121.6)
<b><u>Lung and Bronchus</u></b>									
Male	2	2.8	nc	(nc-nc)					
Female	1	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	25	23.6	106.1	(68.6-156.6)	Male	21	14.7	143.3	(88.7-219.1)
Female	10	8.5	117.3	(56.1-215.7)	Female	16	11.5	139.0	(79.4-225.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	4.6	175.6	(75.6-346.0)	Male	7	3.7	188.4	(75.5-388.1)
Female	6	3.7	164.0	(59.9-357.0)	Female	1	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	14	12.9	108.3	(59.2-181.8)
Female	96	85.0	113.0	(91.5-138.0)	Female	11	10.8	101.5	(50.6-181.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.5	nc	(nc-nc)	Male	10	8.9	113.0	(54.1-207.8)
<b><u>Colon / Rectum</u></b>					Female	4	4.1	nc	(nc-nc)
Male	32	29.6	108.1	(73.9-152.6)	<b><u>Ovary</u></b>				
Female	17	28.8	59.0	(34.3-94.4)	Female	13	8.2	158.9	(84.5-271.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	6.1	98.8	(36.1-215.0)	Male	10	7.4	135.9	(65.0-249.9)
Female	1	1.7	nc	(nc-nc)	Female	6	7.6	78.9	(28.8-171.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	1.9	nc	(nc-nc)	Male	122	84.4	144.6	(120.1-172.7)
Female	0	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	5.6	106.7	(39.0-232.2)
Male	13	12.0	108.7	(57.8-186.0)	Female	3	3.2	nc	(nc-nc)
Female	9	7.0	129.4	(59.0-245.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.9	nc	(nc-nc)
Male	5	3.5	144.6	(46.6-337.4)	<b><u>Thyroid</u></b>				
Female	2	1.0	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	14.0	50.0	(20.0-103.0)
Male	12	8.2	145.9	(75.3-254.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	6.1	98.2	(35.9-213.8)	Female	17	18.7	90.8	(52.8-145.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	6.1	nc	(nc-nc)	Male	370	307.7	120.3	(108.3-133.2)
Female	3	2.1	nc	(nc-nc)	Female	295	295.2	99.9	(88.8-112.0)
<b><u>Lung and Bronchus</u></b>									
Male	43	42.9	100.3	(72.6-135.1)					
Female	34	41.6	81.6	(56.5-114.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	46	36.9	124.6	(91.2-166.2)	Male	10	22.3	44.9	(21.5-82.7)
Female	10	13.5	73.9	(35.4-135.9)	Female	13	17.0	76.6	(40.8-131.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	6.5	nc	(nc-nc)	Male	6	5.8	103.3	(37.7-224.9)
Female	11	5.3	206.5	(102.9-369.5)	Female	5	4.4	112.7	(36.3-263.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	20	19.4	103.1	(63.0-159.3)
Female	138	128.7	107.3	(90.1-126.7)	Female	24	16.9	142.2	(91.1-211.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	4.9	nc	(nc-nc)	Male	16	13.5	118.6	(67.8-192.7)
<b><u>Colon / Rectum</u></b>					Female	9	6.3	142.0	(64.8-269.6)
Male	42	45.9	91.5	(66.0-123.7)	<b><u>Ovary</u></b>				
Female	49	44.8	109.4	(81.0-144.7)	Female	9	12.6	71.4	(32.6-135.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	9.5	83.9	(36.1-165.4)	Male	9	11.5	78.3	(35.7-148.6)
Female	3	2.6	nc	(nc-nc)	Female	13	12.0	108.3	(57.6-185.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.6	nc	(nc-nc)	Male	125	136.5	91.5	(76.2-109.1)
Female	1	2.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	8.7	103.3	(47.2-196.2)
Male	26	18.2	142.5	(93.1-208.8)	Female	5	5.0	99.5	(32.1-232.1)
Female	15	10.8	138.6	(77.5-228.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	3.8	158.3	(57.8-344.6)
Male	6	5.5	109.7	(40.1-238.9)	<b><u>Thyroid</u></b>				
Female	2	1.5	nc	(nc-nc)	Male	10	6.3	159.7	(76.5-293.8)
<b><u>Leukemia</u></b>					Female	20	19.5	102.4	(62.5-158.2)
Male	10	12.3	81.6	(39.0-150.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	9.1	109.4	(52.4-201.3)	Female	31	29.6	104.8	(71.2-148.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	12	9.4	127.5	(65.8-222.7)	Male	482	479.7	100.5	(91.7-109.9)
Female	1	3.3	nc	(nc-nc)	Female	486	453.4	107.2	(97.9-117.1)
<b><u>Lung and Bronchus</u></b>									
Male	73	67.6	108.0	(84.6-135.8)					
Female	78	66.9	116.6	(92.2-145.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.5	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	13	11.1	117.4	(62.4-200.7)
Female	0	0.1	nc	(nc-nc)	Female	6	8.8	68.4	(25.0-148.9)
<b><u>Lung and Bronchus</u></b>									
Male	3	1.5	nc	(nc-nc)					
Female	0	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	28	22.5	124.6	(82.8-180.1)	Male	35	14.2	246.5	(171.6-342.8)
Female	5	8.3	60.4	(19.5-140.9)	Female	20	10.9	183.8	(112.2-283.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	4.3	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	4	3.5	nc	(nc-nc)	Female	7	2.7	257.9	(103.3-531.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	13	12.2	106.4	(56.6-181.9)
Female	87	83.5	104.2	(83.5-128.6)	Female	9	10.5	85.9	(39.2-163.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.3	nc	(nc-nc)	Male	16	8.9	179.7	(102.7-291.9)
<b><u>Colon / Rectum</u></b>					Female	4	4.0	nc	(nc-nc)
Male	26	28.6	91.0	(59.4-133.3)	<b><u>Ovary</u></b>				
Female	22	27.4	80.2	(50.3-121.5)	Female	6	8.1	74.5	(27.2-162.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	6.1	81.9	(26.4-191.1)	Male	2	7.1	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	7	7.3	95.6	(38.3-197.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	96	89.1	107.7	(87.3-131.6)
Female	6	1.3	454.4	(165.9-989.0)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	5.4	130.4	(52.2-268.6)
Male	9	11.9	75.8	(34.6-143.9)	Female	3	3.1	nc	(nc-nc)
Female	5	6.9	72.9	(23.5-170.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	2.4	211.2	(68.1-492.8)
Male	2	3.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	7	4.2	166.9	(66.9-343.9)
<b><u>Leukemia</u></b>					Female	13	13.1	99.6	(53.0-170.4)
Male	12	7.7	156.4	(80.7-273.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	5.8	207.6	(107.2-362.7)	Female	16	19.1	83.6	(47.8-135.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	6.1	nc	(nc-nc)	Male	345	304.6	113.3	(101.6-125.9)
Female	1	2.0	nc	(nc-nc)	Female	294	287.2	102.4	(91.0-114.8)
<b><u>Lung and Bronchus</u></b>									
Male	33	42.3	78.1	(53.8-109.7)					
Female	46	41.4	111.1	(81.3-148.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	15.6	140.7	(88.1-213.0)	Male	18	10.1	177.6	(105.2-280.8)
Female	5	5.2	96.8	(31.2-225.9)	Female	2	7.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	3.1	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	0	2.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	11	8.8	125.5	(62.5-224.5)
Female	69	55.7	123.8	(96.3-156.7)	Female	9	6.7	133.5	(60.9-253.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.3	nc	(nc-nc)	Male	5	6.4	78.4	(25.3-183.0)
<b><u>Colon / Rectum</u></b>					Female	2	2.6	nc	(nc-nc)
Male	16	20.1	79.5	(45.4-129.1)	<b><u>Ovary</u></b>				
Female	20	17.3	115.5	(70.5-178.4)	Female	3	5.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	4.3	117.3	(37.8-273.7)	Male	7	5.0	140.2	(56.2-288.9)
Female	1	1.0	nc	(nc-nc)	Female	5	4.6	109.5	(35.3-255.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	55	61.0	90.2	(68.0-117.4)
Female	1	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	3.8	132.7	(42.8-309.8)
Male	7	8.4	83.4	(33.4-171.9)	Female	1	1.9	nc	(nc-nc)
Female	6	4.4	134.9	(49.3-293.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.0	nc	(nc-nc)
Male	4	2.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	9.5	115.6	(57.6-206.9)
Male	7	5.5	128.2	(51.3-264.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	3.7	nc	(nc-nc)	Female	11	12.5	88.3	(44.0-158.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	4.4	nc	(nc-nc)	Male	207	213.2	97.1	(84.3-111.3)
Female	0	1.3	nc	(nc-nc)	Female	205	187.8	109.1	(94.7-125.1)
<b><u>Lung and Bronchus</u></b>									
Male	23	29.1	78.9	(50.0-118.4)					
Female	31	26.1	118.9	(80.8-168.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	16.9	112.2	(67.5-175.2)	Male	13	11.6	112.2	(59.7-191.9)
Female	2	5.8	nc	(nc-nc)	Female	17	9.0	189.3	(110.2-303.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.7	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	0.5	nc	(nc-nc)	Male	16	10.0	159.8	(91.3-259.4)
Female	78	68.2	114.3	(90.4-142.7)	Female	7	7.8	89.9	(36.0-185.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.9	nc	(nc-nc)	Male	6	7.6	79.2	(28.9-172.5)
<b><u>Colon / Rectum</u></b>					Female	5	3.1	160.9	(51.8-375.5)
Male	17	22.6	75.2	(43.8-120.5)	<b><u>Ovary</u></b>				
Female	25	20.1	124.5	(80.6-183.8)	Female	6	6.3	94.7	(34.6-206.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	4.8	104.1	(33.5-242.9)	Male	7	5.5	126.8	(50.8-261.3)
Female	1	1.1	nc	(nc-nc)	Female	11	5.2	211.3	(105.4-378.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	66	68.2	96.7	(74.8-123.1)
Female	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.2	nc	(nc-nc)
Male	5	9.7	51.4	(16.6-120.0)	Female	0	2.2	nc	(nc-nc)
Female	7	5.2	134.0	(53.7-276.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.2	nc	(nc-nc)
Male	5	2.8	180.8	(58.3-421.9)	<b><u>Thyroid</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	7	3.7	187.9	(75.3-387.2)
<b><u>Leukemia</u></b>					Female	29	11.8	246.6	(165.1-354.2)
Male	6	6.3	95.7	(34.9-208.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	4.5	112.3	(36.2-262.1)	Female	13	15.0	86.8	(46.2-148.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.1	nc	(nc-nc)	Male	238	239.2	99.5	(87.3-113.0)
Female	1	1.5	nc	(nc-nc)	Female	268	222.7	120.3	(106.4-135.6)
<b><u>Lung and Bronchus</u></b>									
Male	25	31.8	78.7	(50.9-116.2)					
Female	32	29.5	108.6	(74.3-153.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	4.5	110.5	(35.6-257.8)	Male	3	2.8	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	25	15.0	166.1	(107.5-245.3)	Female	2	1.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.7	nc	(nc-nc)
Male	4	5.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	4.8	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	12	17.3	69.3	(35.8-121.0)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.1	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	2.4	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.0	nc	(nc-nc)	Female	0	3.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	50	60.0	83.3	(61.8-109.8)
Female	0	0.4	nc	(nc-nc)	Female	55	51.7	106.4	(80.2-138.5)
<b><u>Lung and Bronchus</u></b>									
Male	8	8.4	95.5	(41.1-188.2)					
Female	7	7.5	92.8	(37.2-191.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	6	1.8	337.5	(123.2-734.6)
Female	1	1.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	10	10.8	92.8	(44.4-170.7)	Female	2	1.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.6	nc	(nc-nc)
Male	3	3.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	4.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	7	11.0	63.8	(25.6-131.4)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.7	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.5	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.8	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	30	38.5	78.0	(52.6-111.4)
Female	0	0.3	nc	(nc-nc)	Female	31	39.4	78.7	(53.5-111.7)
<b><u>Lung and Bronchus</u></b>									
Male	3	5.4	nc	(nc-nc)					
Female	2	5.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	4.6	nc	(nc-nc)	Male	5	3.1	162.9	(52.5-380.3)
Female	1	1.4	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	18	17.3	104.2	(61.7-164.7)	Female	1	1.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	5	2.0	247.3	(79.7-577.2)
<b><u>Colon / Rectum</u></b>					Female	1	0.8	nc	(nc-nc)
Male	8	6.1	130.8	(56.3-257.7)	<b><u>Ovary</u></b>				
Female	4	4.8	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	16	19.0	84.1	(48.1-136.6)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.1	nc	(nc-nc)
Male	0	2.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	2.9	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.1	nc	(nc-nc)	Female	5	3.9	127.6	(41.1-297.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	61	65.0	93.9	(71.8-120.6)
Female	0	0.4	nc	(nc-nc)	Female	54	55.4	97.4	(73.2-127.1)
<b><u>Lung and Bronchus</u></b>									
Male	2	8.8	nc	(nc-nc)					
Female	7	7.3	95.9	(38.4-197.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	6.3	79.6	(25.6-185.7)	Male	4	4.8	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	16	22.6	70.8	(40.5-115.0)	Female	1	2.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.1	nc	(nc-nc)
Male	9	8.6	104.2	(47.6-197.9)	<b><u>Ovary</u></b>				
Female	9	6.8	131.7	(60.1-250.0)	Female	1	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	32	25.8	124.2	(84.9-175.3)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.6	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.7	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	4.0	nc	(nc-nc)
Male	4	2.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.5	nc	(nc-nc)	Female	4	5.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	94	93.7	100.3	(81.1-122.7)
Female	0	0.5	nc	(nc-nc)	Female	69	75.7	91.2	(70.9-115.4)
<b><u>Lung and Bronchus</u></b>									
Male	17	11.9	142.3	(82.9-227.9)					
Female	16	10.3	154.7	(88.3-251.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	37	34.0	108.9	(76.7-150.1)	Male	22	22.2	99.0	(62.0-149.9)
Female	15	12.8	117.4	(65.7-193.7)	Female	20	18.0	111.3	(67.9-171.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	7.0	114.3	(49.2-225.3)	Male	5	5.5	91.0	(29.3-212.3)
Female	6	5.7	105.3	(38.4-229.1)	Female	3	4.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.0	nc	(nc-nc)	Male	26	19.3	134.6	(87.9-197.3)
Female	124	128.9	96.2	(80.0-114.7)	Female	19	16.4	115.9	(69.8-181.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	5.7	nc	(nc-nc)	Male	9	13.6	66.3	(30.3-125.9)
<b><u>Colon / Rectum</u></b>					Female	4	6.2	nc	(nc-nc)
Male	40	43.7	91.5	(65.3-124.6)	<b><u>Ovary</u></b>				
Female	49	43.4	113.0	(83.6-149.4)	Female	13	12.4	104.5	(55.6-178.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	9.0	99.8	(45.5-189.5)	Male	13	10.8	120.9	(64.3-206.7)
Female	1	2.5	nc	(nc-nc)	Female	8	11.4	70.3	(30.3-138.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	3.1	nc	(nc-nc)	Male	122	127.1	96.0	(79.7-114.6)
Female	5	2.4	205.0	(66.1-478.4)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	8.2	60.9	(19.6-142.1)
Male	21	18.1	116.3	(72.0-177.8)	Female	3	4.9	nc	(nc-nc)
Female	7	10.5	66.4	(26.6-136.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	5.2	134.7	(54.0-277.6)
Male	5	5.2	96.5	(31.1-225.3)	<b><u>Thyroid</u></b>				
Female	4	1.4	nc	(nc-nc)	Male	6	7.0	86.1	(31.4-187.4)
<b><u>Leukemia</u></b>					Female	19	22.5	84.4	(50.8-131.9)
Male	10	12.3	81.5	(39.0-149.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	9.4	53.2	(17.2-124.2)	Female	29	28.5	101.8	(68.1-146.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	9.2	54.1	(17.4-126.3)	Male	439	458.8	95.7	(86.9-105.1)
Female	1	3.2	nc	(nc-nc)	Female	422	448.6	94.1	(85.3-103.5)
<b><u>Lung and Bronchus</u></b>									
Male	50	62.2	80.4	(59.7-106.0)					
Female	59	62.3	94.8	(72.1-122.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	7	6.2	112.1	(44.9-230.9)	Female	0	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	3	1.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	7	5.5	127.0	(50.9-261.6)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.3	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.3	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	19	19.6	96.8	(58.3-151.2)
Female	0	0.1	nc	(nc-nc)	Female	15	18.6	80.5	(45.0-132.8)
<b><u>Lung and Bronchus</u></b>									
Male	2	2.4	nc	(nc-nc)					
Female	2	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Somerset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	30	27.6	108.5	(73.2-154.9)	Male	8	16.2	49.3	(21.2-97.1)
Female	11	11.0	99.7	(49.7-178.3)	Female	11	12.7	86.6	(43.2-155.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	4.7	107.3	(34.6-250.4)	Male	3	4.3	nc	(nc-nc)
Female	6	4.0	149.5	(54.6-325.3)	Female	4	3.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	19	14.2	133.8	(80.5-208.9)
Female	74	97.1	76.2	(59.9-95.7)	Female	12	13.4	89.3	(46.1-156.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	3.5	228.5	(98.4-450.3)	Male	9	9.7	92.9	(42.4-176.4)
<b><u>Colon / Rectum</u></b>					Female	3	4.9	nc	(nc-nc)
Male	44	33.9	129.8	(94.3-174.2)	<b><u>Ovary</u></b>				
Female	26	36.7	70.7	(46.2-103.7)	Female	16	9.7	165.6	(94.6-268.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	7.0	114.3	(49.2-225.1)	Male	12	8.5	140.4	(72.5-245.3)
Female	3	2.2	nc	(nc-nc)	Female	8	9.9	81.1	(34.9-159.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	95	99.9	95.1	(76.9-116.3)
Female	1	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	11	6.5	169.8	(84.7-303.9)
Male	14	13.3	105.1	(57.4-176.4)	Female	9	4.2	215.3	(98.3-408.8)
Female	5	8.4	59.7	(19.2-139.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.6	nc	(nc-nc)
Male	2	4.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	1	4.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	13.7	73.2	(35.1-134.7)
Male	10	9.0	111.5	(53.4-205.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	7.2	151.9	(75.7-271.8)	Female	27	22.2	121.5	(80.1-176.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	6.8	73.3	(23.6-171.1)	Male	341	352.7	96.7	(86.7-107.5)
Female	4	2.6	nc	(nc-nc)	Female	326	352.3	92.5	(82.8-103.1)
<b><u>Lung and Bronchus</u></b>									
Male	35	50.5	69.3	(48.3-96.4)					
Female	43	53.2	80.9	(58.5-108.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	45	58.8	76.5	(55.8-102.3)	Male	33	40.3	81.8	(56.3-114.9)
Female	25	25.0	100.0	(64.7-147.6)	Female	24	37.9	63.3	(40.5-94.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	13.3	90.5	(46.7-158.1)	Male	6	9.4	63.5	(23.2-138.2)
Female	10	11.6	86.0	(41.2-158.2)	Female	7	8.1	86.4	(34.6-178.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	5	1.6	304.9	(98.3-711.5)	Male	28	35.0	80.0	(53.2-115.7)
Female	200	243.0	82.3	(71.3-94.5)	Female	26	32.4	80.1	(52.3-117.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	10	11.7	85.7	(41.0-157.5)	Male	30	23.1	129.6	(87.5-185.1)
<b><u>Colon / Rectum</u></b>					Female	10	12.3	81.1	(38.8-149.1)
Male	67	75.5	88.8	(68.8-112.7)	<b><u>Ovary</u></b>				
Female	85	84.5	100.6	(80.4-124.4)	Female	14	24.3	57.7	(31.5-96.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	15.3	78.3	(40.4-136.8)	Male	24	18.5	130.1	(83.3-193.6)
Female	8	4.8	165.2	(71.1-325.6)	Female	14	22.2	63.1	(34.5-105.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	11	8.5	129.8	(64.7-232.3)	Male	158	214.1	73.8	(62.8-86.3)
Female	6	6.5	91.7	(33.5-199.6)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	22	14.3	153.8	(96.4-232.9)
Male	25	31.3	80.0	(51.8-118.1)	Female	11	9.6	114.5	(57.1-204.9)
Female	12	20.3	59.1	(30.5-103.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	9	15.4	58.4	(26.7-110.9)
Male	9	8.8	102.8	(46.9-195.1)	<b><u>Thyroid</u></b>				
Female	6	2.8	216.8	(79.2-472.0)	Male	19	13.9	136.9	(82.4-213.9)
<b><u>Leukemia</u></b>					Female	50	48.2	103.7	(77.0-136.7)
Male	16	22.2	72.1	(41.2-117.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	24	18.6	129.2	(82.7-192.2)	Female	41	53.9	76.1	(54.6-103.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	23	15.6	147.0	(93.2-220.6)	Male	726	805.4	90.1	(83.7-96.9)
Female	5	6.1	81.4	(26.2-189.9)	Female	753	876.0	86.0	(79.9-92.3)
<b><u>Lung and Bronchus</u></b>									
Male	127	107.1	118.6	(98.9-141.1)					
Female	109	121.2	89.9	(73.8-108.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	22.0	122.7	(80.8-178.5)	Male	12	12.8	93.6	(48.3-163.4)
Female	11	8.8	125.6	(62.6-224.8)	Female	12	10.9	110.4	(57.0-192.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.7	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	15	11.3	132.9	(74.3-219.2)
Female	100	77.4	129.1	(105.1-157.1)	Female	12	10.9	110.5	(57.0-193.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.0	nc	(nc-nc)	Male	10	7.6	131.6	(63.0-242.1)
<b><u>Colon / Rectum</u></b>					Female	5	4.0	126.3	(40.7-294.7)
Male	31	26.9	115.1	(78.2-163.3)	<b><u>Ovary</u></b>				
Female	18	29.3	61.5	(36.4-97.2)	Female	12	7.8	152.9	(78.9-267.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	5.5	91.1	(29.4-212.5)	Male	6	6.8	88.6	(32.4-193.0)
Female	0	1.7	nc	(nc-nc)	Female	8	7.8	102.4	(44.1-201.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	81	77.6	104.4	(82.9-129.8)
Female	1	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	5.2	97.1	(31.3-226.5)
Male	15	10.4	144.0	(80.6-237.6)	Female	4	3.3	nc	(nc-nc)
Female	3	6.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	2.1	nc	(nc-nc)
Male	4	3.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	12.2	90.3	(45.0-161.6)
Male	6	7.2	83.6	(30.5-182.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	6.0	83.8	(27.0-195.5)	Female	26	17.6	147.5	(96.3-216.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	5.4	nc	(nc-nc)	Male	287	277.7	103.3	(91.7-116.0)
Female	0	2.1	nc	(nc-nc)	Female	298	284.2	104.9	(93.3-117.5)
<b><u>Lung and Bronchus</u></b>									
Male	42	39.7	105.9	(76.3-143.1)					
Female	39	42.0	92.9	(66.0-127.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	5.6	106.6	(38.9-231.9)	Male	5	3.9	126.6	(40.8-295.5)
Female	3	2.0	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	23	23.1	99.7	(63.2-149.6)	Female	3	2.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.1	nc	(nc-nc)
Male	6	7.6	78.8	(28.8-171.4)	<b><u>Ovary</u></b>				
Female	3	6.9	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	33	23.2	142.0	(97.7-199.4)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.4	nc	(nc-nc)
Male	1	3.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.9	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	4.1	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.5	nc	(nc-nc)	Female	5	5.2	96.2	(31.0-224.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	78	80.9	96.4	(76.2-120.3)
Female	1	0.5	nc	(nc-nc)	Female	64	76.1	84.1	(64.8-107.5)
<b><u>Lung and Bronchus</u></b>									
Male	6	10.5	57.0	(20.8-124.1)					
Female	5	10.0	49.9	(16.1-116.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	7.6	171.4	(91.2-293.1)	Male	12	5.6	213.7	(110.3-373.2)
Female	3	2.4	nc	(nc-nc)	Female	6	4.4	137.3	(50.1-298.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	5	1.3	380.5	(122.6-888.1)
Female	1	1.4	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
Female	38	31.4	121.0	(85.7-166.2)	Female	2	3.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.5	nc	(nc-nc)	Male	6	3.7	163.6	(59.7-356.1)
<b><u>Colon / Rectum</u></b>					Female	1	1.4	nc	(nc-nc)
Male	15	10.4	143.9	(80.5-237.3)	<b><u>Ovary</u></b>				
Female	12	8.4	143.0	(73.8-249.9)	Female	2	2.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	6	2.5	238.1	(87.0-518.4)
Female	0	0.5	nc	(nc-nc)	Female	5	2.1	234.7	(75.6-547.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	38	32.0	118.6	(83.9-162.8)
Female	2	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.9	nc	(nc-nc)
Male	3	4.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.4	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	6.2	80.9	(26.1-188.8)
Male	5	3.0	165.1	(53.2-385.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.1	nc	(nc-nc)	Female	12	6.9	174.5	(90.1-304.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.4	nc	(nc-nc)	Male	152	112.4	135.2	(114.6-158.5)
Female	0	0.7	nc	(nc-nc)	Female	124	100.3	123.6	(102.8-147.4)
<b><u>Lung and Bronchus</u></b>									
Male	15	14.4	104.3	(58.3-172.0)					
Female	18	12.5	144.4	(85.5-228.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	18.4	108.4	(66.2-167.5)	Male	6	11.5	52.3	(19.1-113.9)
Female	7	7.5	92.8	(37.2-191.1)	Female	1	9.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.6	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)	Female	0	2.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	9	10.1	89.0	(40.6-168.9)
Female	56	69.0	81.2	(61.3-105.4)	Female	7	9.5	74.1	(29.7-152.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.9	nc	(nc-nc)	Male	7	6.8	103.0	(41.2-212.1)
<b><u>Colon / Rectum</u></b>					Female	3	3.5	nc	(nc-nc)
Male	39	23.2	168.3	(119.7-230.1)	<b><u>Ovary</u></b>				
Female	23	25.7	89.6	(56.8-134.4)	Female	2	6.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	4.7	107.3	(34.6-250.4)	Male	7	5.7	122.2	(49.0-251.8)
Female	0	1.5	nc	(nc-nc)	Female	4	6.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	48	65.0	73.9	(54.5-98.0)
Female	1	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	4.4	113.7	(36.6-265.3)
Male	9	9.2	98.0	(44.7-186.0)	Female	3	2.9	nc	(nc-nc)
Female	9	5.8	154.4	(70.4-293.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.7	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	11.3	61.8	(24.7-127.3)
Male	9	6.6	137.3	(62.7-260.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	5.4	130.7	(52.4-269.4)	Female	18	15.2	118.1	(69.9-186.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.7	nc	(nc-nc)	Male	219	239.7	91.4	(79.7-104.3)
Female	1	1.8	nc	(nc-nc)	Female	198	249.9	79.2	(68.6-91.1)
<b><u>Lung and Bronchus</u></b>									
Male	26	33.1	78.6	(51.3-115.2)					
Female	30	35.9	83.7	(56.4-119.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	9.6	104.4	(50.0-192.0)	Male	2	6.4	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)	Female	2	4.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.0	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.6	107.8	(39.4-234.6)
Female	43	35.3	121.9	(88.2-164.2)	Female	6	4.3	138.5	(50.6-301.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.7	nc	(nc-nc)
Male	13	12.5	104.1	(55.4-178.0)	<b><u>Ovary</u></b>				
Female	24	11.2	214.3	(137.3-318.9)	Female	3	3.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.6	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	43	35.8	120.2	(87.0-161.9)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.3	nc	(nc-nc)
Male	3	5.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.5	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	6.2	nc	(nc-nc)
Male	2	3.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.5	nc	(nc-nc)	Female	9	7.8	115.0	(52.5-218.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.7	nc	(nc-nc)	Male	130	130.4	99.7	(83.3-118.4)
Female	2	0.8	nc	(nc-nc)	Female	128	120.1	106.6	(88.9-126.7)
<b><u>Lung and Bronchus</u></b>									
Male	14	17.5	80.1	(43.8-134.4)					
Female	16	16.5	96.8	(55.3-157.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	12.6	103.5	(55.1-177.0)	Male	6	8.2	72.8	(26.6-158.4)
Female	6	4.2	142.4	(52.0-310.0)	Female	3	6.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.6	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	9	7.2	125.5	(57.3-238.2)
Female	38	45.3	84.0	(59.4-115.3)	Female	7	5.5	126.3	(50.6-260.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.9	nc	(nc-nc)	Male	2	5.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	2.2	nc	(nc-nc)
Male	23	16.3	141.2	(89.5-211.9)	<b><u>Ovary</u></b>				
Female	24	14.2	169.5	(108.5-252.1)	Female	3	4.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	3.4	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	33	48.7	67.8	(46.6-95.2)
Female	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.0	nc	(nc-nc)
Male	6	6.8	88.3	(32.3-192.3)	Female	1	1.6	nc	(nc-nc)
Female	8	3.6	220.3	(94.8-434.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.9	nc	(nc-nc)
Male	5	2.0	254.0	(81.9-592.7)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	7.9	63.2	(20.4-147.4)
Male	4	4.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	3.1	nc	(nc-nc)	Female	11	10.2	107.9	(53.8-193.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	3.5	nc	(nc-nc)	Male	153	172.2	88.8	(75.3-104.1)
Female	1	1.1	nc	(nc-nc)	Female	155	153.7	100.8	(85.6-118.0)
<b><u>Lung and Bronchus</u></b>									
Male	22	23.3	94.6	(59.3-143.2)					
Female	19	21.2	89.5	(53.9-139.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	95	137.7	69.0	(55.8-84.3)	Male	30	87.1	34.4	(23.2-49.2)
Female	47	55.9	84.0	(61.7-111.7)	Female	38	78.5	48.4	(34.3-66.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	19	28.6	66.3	(39.9-103.6)	Male	21	21.7	96.9	(60.0-148.1)
Female	18	25.8	69.9	(41.4-110.5)	Female	18	18.3	98.4	(58.3-155.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	8	3.8	210.6	(90.7-414.9)	Male	48	77.3	62.1	(45.8-82.3)
Female	511	544.8	93.8	(85.8-102.3)	Female	62	71.8	86.4	(66.2-110.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	35	23.6	148.0	(103.1-205.9)	Male	61	51.3	119.0	(91.0-152.8)
<b><u>Colon / Rectum</u></b>					Female	28	27.0	103.6	(68.9-149.8)
Male	148	173.1	85.5	(72.3-100.4)	<b><u>Ovary</u></b>				
Female	153	188.3	81.2	(68.9-95.2)	Female	43	53.6	80.2	(58.0-108.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	29	35.1	82.7	(55.4-118.8)	Male	48	42.8	112.1	(82.7-148.7)
Female	5	10.9	45.9	(14.8-107.1)	Female	35	49.8	70.3	(49.0-97.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	18	14.5	124.6	(73.8-196.9)	Male	474	489.6	96.8	(88.3-105.9)
Female	9	12.2	73.7	(33.6-140.0)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	54	32.9	164.1	(123.3-214.1)
Male	76	69.6	109.3	(86.1-136.8)	Female	27	21.3	127.0	(83.7-184.8)
Female	45	45.5	98.9	(72.1-132.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	16	23.0	69.7	(39.8-113.2)
Male	25	20.0	124.9	(80.8-184.4)	<b><u>Thyroid</u></b>				
Female	6	6.2	97.0	(35.4-211.2)	Male	15	26.9	55.8	(31.2-92.1)
<b><u>Leukemia</u></b>					Female	66	96.4	68.5	(52.9-87.1)
Male	30	50.9	59.0	(39.8-84.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	28	41.8	66.9	(44.5-96.7)	Female	116	121.2	95.7	(79.1-114.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	41	35.3	116.2	(83.3-157.6)	Male	1643	1813.6	90.6	(86.3-95.1)
Female	12	13.8	86.8	(44.8-151.6)	Female	1714	1936.9	88.5	(84.4-92.8)
<b><u>Lung and Bronchus</u></b>									
Male	264	248.8	106.1	(93.7-119.7)					
Female	259	272.8	94.9	(83.7-107.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	7.1	155.2	(77.4-277.7)	Male	7	5.0	139.4	(55.8-287.2)
Female	4	2.1	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	9	4.3	207.2	(94.6-393.4)
Female	27	27.5	98.2	(64.7-142.9)	Female	4	3.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.2	nc	(nc-nc)
Male	6	9.6	62.5	(22.8-136.0)	<b><u>Ovary</u></b>				
Female	9	7.5	120.0	(54.8-227.8)	Female	3	2.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.1	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	27	29.1	92.9	(61.2-135.2)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	1.8	nc	(nc-nc)
Male	5	4.2	119.0	(38.4-277.8)	Female	1	0.8	nc	(nc-nc)
Female	6	2.0	293.6	(107.2-639.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.1	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	5.2	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.7	nc	(nc-nc)	Female	6	6.0	99.6	(36.4-216.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.2	nc	(nc-nc)	Male	90	102.3	88.0	(70.8-108.2)
Female	0	0.6	nc	(nc-nc)	Female	88	87.8	100.3	(80.4-123.5)
<b><u>Lung and Bronchus</u></b>									
Male	8	13.3	60.0	(25.8-118.3)					
Female	8	11.0	72.9	(31.4-143.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	4.2	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	7	12.9	54.4	(21.8-112.0)	Female	1	1.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.6	nc	(nc-nc)
Male	5	5.1	98.0	(31.6-228.8)	<b><u>Ovary</u></b>				
Female	0	4.6	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	7	14.7	47.8	(19.1-98.4)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.0	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.3	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	1.8	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.9	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	33	52.3	63.1	(43.4-88.7)
Female	0	0.3	nc	(nc-nc)	Female	28	45.6	61.4	(40.8-88.8)
<b><u>Lung and Bronchus</u></b>									
Male	7	7.6	91.7	(36.7-188.9)					
Female	6	6.9	87.1	(31.8-189.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	39	29.9	130.6	(92.8-178.5)	Male	11	17.7	62.0	(30.9-111.0)
Female	6	11.8	50.8	(18.6-110.7)	Female	13	14.0	92.6	(49.3-158.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	5.2	115.7	(42.3-251.9)	Male	5	4.6	107.9	(34.8-251.8)
Female	3	4.5	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	22	15.5	141.5	(88.7-214.3)
Female	114	105.0	108.6	(89.5-130.4)	Female	16	14.4	111.0	(63.4-180.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	4.0	225.4	(102.8-427.8)	Male	7	10.5	66.8	(26.8-137.6)
<b><u>Colon / Rectum</u></b>					Female	10	5.3	189.7	(90.8-348.9)
Male	40	36.9	108.5	(77.5-147.8)	<b><u>Ovary</u></b>				
Female	50	39.5	126.5	(93.9-166.7)	Female	12	10.4	115.6	(59.7-201.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	7.5	147.4	(73.5-263.8)	Male	8	9.2	86.9	(37.4-171.2)
Female	3	2.3	nc	(nc-nc)	Female	10	10.6	94.7	(45.3-174.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	114	105.2	108.4	(89.4-130.2)
Female	4	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	7.0	127.8	(58.3-242.6)
Male	16	14.4	111.3	(63.6-180.7)	Female	6	4.5	132.8	(48.5-289.0)
Female	9	9.0	100.0	(45.6-189.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	3.1	161.7	(52.1-377.3)
Male	9	4.3	211.3	(96.4-401.2)	<b><u>Thyroid</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	15	15.6	96.3	(53.9-158.9)
Male	15	9.9	151.2	(84.6-249.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	8.0	113.2	(51.6-214.8)	Female	22	23.5	93.7	(58.7-141.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	12	7.3	163.3	(84.3-285.3)	Male	429	379.5	113.0	(102.6-124.3)
Female	4	2.8	nc	(nc-nc)	Female	408	380.4	107.3	(97.1-118.2)
<b><u>Lung and Bronchus</u></b>									
Male	60	53.9	111.4	(85.0-143.4)					
Female	61	56.6	107.7	(82.4-138.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	39	30.8	126.6	(90.0-173.0)	Male	19	19.5	97.4	(58.6-152.0)
Female	14	12.1	115.6	(63.1-193.9)	Female	15	15.9	94.2	(52.7-155.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	6.0	83.9	(27.0-195.8)	Male	9	4.9	182.2	(83.1-345.9)
Female	4	5.0	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	25	17.0	147.2	(95.2-217.3)
Female	129	118.8	108.6	(90.6-129.0)	Female	19	15.3	124.3	(74.8-194.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	4.7	147.9	(59.2-304.7)	Male	22	12.1	182.5	(114.3-276.3)
<b><u>Colon / Rectum</u></b>					Female	9	5.8	155.2	(70.8-294.6)
Male	49	39.2	125.1	(92.5-165.4)	<b><u>Ovary</u></b>				
Female	54	40.5	133.4	(100.2-174.1)	Female	20	11.6	172.8	(105.5-266.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	15	8.2	182.9	(102.3-301.6)	Male	16	9.7	164.4	(93.9-266.9)
Female	6	2.4	254.4	(92.9-553.8)	Female	7	10.8	65.0	(26.1-134.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	116	116.6	99.5	(82.2-119.4)
Female	3	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	7.4	95.0	(38.1-195.8)
Male	10	16.0	62.3	(29.8-114.6)	Female	6	4.5	132.0	(48.2-287.2)
Female	17	9.8	172.8	(100.6-276.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	3.9	129.4	(41.7-302.1)
Male	6	4.7	127.5	(46.6-277.6)	<b><u>Thyroid</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	10	5.9	170.9	(81.8-314.4)
<b><u>Leukemia</u></b>					Female	26	19.0	137.1	(89.5-200.8)
Male	8	10.7	74.7	(32.2-147.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	8.4	95.1	(40.9-187.4)	Female	23	27.0	85.1	(53.9-127.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	8.3	60.1	(19.4-140.3)	Male	456	412.2	110.6	(100.7-121.3)
Female	4	3.0	nc	(nc-nc)	Female	489	414.9	117.8	(107.6-128.8)
<b><u>Lung and Bronchus</u></b>									
Male	62	56.8	109.1	(83.6-139.8)					
Female	72	59.7	120.6	(94.3-151.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	5.2	135.8	(54.4-279.9)	Male	6	3.9	154.1	(56.3-335.4)
Female	2	1.8	nc	(nc-nc)	Female	10	3.1	323.4	(154.8-594.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	6	3.3	182.0	(66.5-396.2)
Female	31	23.1	134.1	(91.1-190.3)	Female	2	2.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	1.0	nc	(nc-nc)
Male	3	7.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	8	6.2	128.4	(55.3-253.1)	Female	1	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	32	23.6	135.8	(92.9-191.7)
Female	2	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.3	nc	(nc-nc)
Male	1	3.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.9	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	4.3	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.4	nc	(nc-nc)	Female	5	5.2	95.9	(30.9-223.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	83	79.2	104.7	(83.4-129.8)
Female	1	0.5	nc	(nc-nc)	Female	88	73.5	119.7	(96.0-147.4)
<b><u>Lung and Bronchus</u></b>									
Male	4	10.0	nc	(nc-nc)					
Female	9	9.3	96.8	(44.2-183.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	10.1	69.2	(27.7-142.6)	Male	3	6.5	nc	(nc-nc)
Female	4	3.4	nc	(nc-nc)	Female	5	4.8	103.5	(33.3-241.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	5	5.7	88.1	(28.4-205.7)
Female	40	35.8	111.7	(79.8-152.2)	Female	5	4.4	113.6	(36.6-265.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.5	nc	(nc-nc)	Male	1	4.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.7	nc	(nc-nc)
Male	14	13.0	107.9	(58.9-181.1)	<b><u>Ovary</u></b>				
Female	12	11.4	105.3	(54.4-184.0)	Female	1	3.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	31	39.1	79.3	(53.9-112.6)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	2.4	nc	(nc-nc)
Male	4	5.4	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.3	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	6.0	149.1	(68.0-283.1)
Male	1	3.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.5	nc	(nc-nc)	Female	12	8.1	148.8	(76.8-260.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	105	137.3	76.5	(62.6-92.6)
Female	0	0.8	nc	(nc-nc)	Female	134	121.8	110.0	(92.1-130.3)
<b><u>Lung and Bronchus</u></b>									
Male	14	18.7	74.8	(40.9-125.5)					
Female	17	17.0	99.7	(58.1-159.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	15.6	108.8	(63.4-174.3)	Male	14	11.0	126.8	(69.2-212.7)
Female	8	5.3	151.2	(65.1-297.9)	Female	8	8.4	95.0	(40.9-187.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	3.6	167.4	(61.1-364.3)	Male	3	2.7	nc	(nc-nc)
Female	6	2.7	221.1	(80.8-481.3)	Female	3	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	10	9.5	105.8	(50.6-194.6)
Female	80	63.9	125.3	(99.3-155.9)	Female	12	7.1	168.2	(86.8-293.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.8	nc	(nc-nc)	Male	3	7.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	2.9	nc	(nc-nc)
Male	26	21.2	122.5	(80.0-179.5)	<b><u>Ovary</u></b>				
Female	17	18.2	93.3	(54.3-149.3)	Female	2	5.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	4.6	nc	(nc-nc)	Male	1	5.1	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	5	4.7	106.5	(34.3-248.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	69	65.8	104.8	(81.6-132.7)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.9	nc	(nc-nc)
Male	6	9.3	64.6	(23.6-140.7)	Female	2	2.0	nc	(nc-nc)
Female	4	4.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.2	nc	(nc-nc)
Male	0	2.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	8	3.6	219.6	(94.6-432.8)
<b><u>Leukemia</u></b>					Female	9	11.3	79.7	(36.4-151.2)
Male	11	5.9	185.1	(92.3-331.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	4.2	143.7	(52.5-312.8)	Female	11	14.2	77.6	(38.7-138.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.9	nc	(nc-nc)	Male	217	227.1	95.6	(83.3-109.2)
Female	1	1.4	nc	(nc-nc)	Female	216	206.5	104.6	(91.1-119.5)
<b><u>Lung and Bronchus</u></b>									
Male	18	29.8	60.5	(35.8-95.6)					
Female	23	26.6	86.4	(54.8-129.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	10	10.0	99.8	(47.8-183.5)	Female	1	1.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.5	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	3.4	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	10	8.8	113.8	(54.5-209.4)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.8	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	2.2	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.8	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	33	33.2	99.3	(68.3-139.5)
Female	0	0.2	nc	(nc-nc)	Female	31	35.6	87.0	(59.1-123.5)
<b><u>Lung and Bronchus</u></b>									
Male	3	4.2	nc	(nc-nc)					
Female	1	4.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	7.5	66.9	(21.6-156.1)	Male	5	5.5	91.4	(29.5-213.4)
Female	2	2.3	nc	(nc-nc)	Female	0	4.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.2	nc	(nc-nc)	Male	10	4.7	212.6	(101.8-391.0)
Female	28	29.3	95.4	(63.4-137.9)	Female	3	3.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.3	nc	(nc-nc)
Male	5	10.4	48.2	(15.5-112.5)	<b><u>Ovary</u></b>				
Female	8	7.8	102.5	(44.1-202.0)	Female	1	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.2	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	39	31.5	123.8	(88.0-169.2)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.9	nc	(nc-nc)
Male	5	4.5	109.9	(35.4-256.6)	Female	1	0.8	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.3	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	5.8	120.7	(48.3-248.6)
Male	0	2.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.9	nc	(nc-nc)	Female	5	6.5	76.9	(24.8-179.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	110	110.4	99.6	(81.9-120.0)
Female	0	0.6	nc	(nc-nc)	Female	95	93.8	101.3	(81.9-123.8)
<b><u>Lung and Bronchus</u></b>									
Male	12	14.1	85.2	(44.0-148.9)					
Female	19	11.7	162.5	(97.8-253.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	20.0	85.2	(49.6-136.4)	Male	10	11.7	85.3	(40.9-157.0)
Female	15	7.8	193.2	(108.1-318.8)	Female	19	9.3	203.8	(122.6-318.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	5	3.1	161.2	(52.0-376.3)
Female	7	2.9	238.4	(95.5-491.2)	Female	0	2.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	17	10.4	163.8	(95.4-262.3)
Female	75	69.9	107.3	(84.4-134.5)	Female	10	9.5	105.0	(50.3-193.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.7	nc	(nc-nc)	Male	0	7.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	3.5	nc	(nc-nc)
Male	25	24.8	100.8	(65.2-148.9)	<b><u>Ovary</u></b>				
Female	26	26.8	97.1	(63.4-142.3)	Female	9	6.9	130.9	(59.7-248.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	4.9	nc	(nc-nc)	Male	5	6.1	81.7	(26.3-190.6)
Female	1	1.5	nc	(nc-nc)	Female	5	7.0	71.0	(22.9-165.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	71	67.7	104.9	(81.9-132.3)
Female	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.7	nc	(nc-nc)
Male	6	9.4	63.7	(23.3-138.7)	Female	4	3.1	nc	(nc-nc)
Female	3	5.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.8	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	8	3.2	251.9	(108.5-496.5)
<b><u>Leukemia</u></b>					Female	9	10.3	87.3	(39.8-165.7)
Male	16	6.7	238.9	(136.5-388.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	5.3	112.6	(41.1-245.1)	Female	22	15.3	143.4	(89.9-217.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	4.8	nc	(nc-nc)	Male	250	249.4	100.2	(88.2-113.5)
Female	1	1.9	nc	(nc-nc)	Female	268	251.6	106.5	(94.1-120.1)
<b><u>Lung and Bronchus</u></b>									
Male	31	35.1	88.4	(60.1-125.5)					
Female	30	36.2	83.0	(56.0-118.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	20.1	114.2	(72.4-171.4)	Male	12	12.6	94.9	(49.0-165.8)
Female	12	7.4	162.9	(84.1-284.6)	Female	6	9.7	62.1	(22.7-135.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.8	131.9	(42.5-307.9)	Male	2	3.2	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	7	11.0	63.5	(25.4-130.9)
Female	58	72.4	80.1	(60.8-103.5)	Female	8	9.3	86.0	(37.0-169.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	2.9	174.5	(56.2-407.3)	Male	6	7.8	76.8	(28.0-167.1)
<b><u>Colon / Rectum</u></b>					Female	2	3.5	nc	(nc-nc)
Male	21	25.6	82.1	(50.8-125.5)	<b><u>Ovary</u></b>				
Female	32	24.7	129.7	(88.7-183.0)	Female	9	7.0	127.8	(58.3-242.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	5.3	94.1	(30.3-219.5)	Male	7	6.3	110.3	(44.2-227.3)
Female	1	1.4	nc	(nc-nc)	Female	9	6.6	137.3	(62.6-260.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.6	nc	(nc-nc)	Male	84	75.3	111.6	(89.0-138.2)
Female	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	4.8	nc	(nc-nc)
Male	10	10.4	96.5	(46.2-177.4)	Female	3	2.8	nc	(nc-nc)
Female	6	6.0	100.4	(36.7-218.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	2.4	204.7	(66.0-477.7)
Male	6	3.0	197.0	(71.9-428.8)	<b><u>Thyroid</u></b>				
Female	2	0.8	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	11.5	95.8	(47.7-171.4)
Male	3	6.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	5.1	138.1	(55.3-284.5)	Female	13	16.4	79.2	(42.1-135.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	5.4	nc	(nc-nc)	Male	272	267.2	101.8	(90.0-114.6)
Female	3	1.8	nc	(nc-nc)	Female	241	252.4	95.5	(83.8-108.3)
<b><u>Lung and Bronchus</u></b>									
Male	47	36.9	127.4	(93.6-169.5)					
Female	30	36.3	82.5	(55.7-117.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Taunton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	49	54.0	90.7	(67.1-120.0)	Male	19	35.3	53.8	(32.4-84.0)
Female	20	21.6	92.4	(56.4-142.7)	Female	17	30.3	56.1	(32.7-89.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	14	11.2	124.6	(68.1-209.1)	Male	11	8.7	126.8	(63.2-226.9)
Female	10	9.6	103.8	(49.7-190.8)	Female	6	7.1	84.7	(30.9-184.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	32	30.7	104.1	(71.2-146.9)
Female	212	212.3	99.9	(86.9-114.2)	Female	26	27.7	93.7	(61.2-137.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	14	9.3	151.2	(82.6-253.6)	Male	26	21.3	122.0	(79.7-178.8)
<b><u>Colon / Rectum</u></b>					Female	13	10.4	124.4	(66.2-212.8)
Male	69	69.0	100.0	(77.8-126.5)	<b><u>Ovary</u></b>				
Female	78	73.4	106.2	(83.9-132.5)	Female	21	20.8	101.0	(62.5-154.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	15	14.3	105.1	(58.8-173.3)	Male	27	17.1	158.3	(104.3-230.3)
Female	1	4.2	nc	(nc-nc)	Female	24	19.3	124.4	(79.7-185.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	9	5.4	165.3	(75.4-313.8)	Male	174	201.9	86.2	(73.9-100.0)
Female	8	4.4	182.9	(78.7-360.3)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	25	13.0	192.1	(124.3-283.6)
Male	31	28.5	108.7	(73.8-154.2)	Female	10	8.3	120.4	(57.6-221.4)
Female	24	17.5	136.8	(87.6-203.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	10	9.0	111.0	(53.2-204.2)
Male	9	8.2	109.7	(50.1-208.3)	<b><u>Thyroid</u></b>				
Female	1	2.4	nc	(nc-nc)	Male	8	11.2	71.6	(30.8-141.2)
<b><u>Leukemia</u></b>					Female	41	37.2	110.2	(79.0-149.5)
Male	14	19.6	71.6	(39.1-120.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	15.9	56.5	(25.8-107.3)	Female	41	47.2	86.8	(62.3-117.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	20	14.5	138.0	(84.3-213.2)	Male	771	729.6	105.7	(98.3-113.4)
Female	6	5.4	112.1	(40.9-244.0)	Female	750	750.3	100.0	(92.9-107.4)
<b><u>Lung and Bronchus</u></b>									
Male	138	99.1	139.3	(117.0-164.6)					
Female	116	104.9	110.6	(91.4-132.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	7.8	89.5	(35.8-184.3)	Male	7	5.2	133.9	(53.6-275.9)
Female	2	2.8	nc	(nc-nc)	Female	0	3.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
Female	36	28.0	128.4	(89.9-177.8)	Female	3	3.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.4	nc	(nc-nc)
Male	7	10.2	68.5	(27.4-141.1)	<b><u>Ovary</u></b>				
Female	5	9.3	53.5	(17.2-124.9)	Female	6	2.7	221.6	(80.9-482.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	2.2	230.4	(74.2-537.6)	Male	2	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	29	30.9	94.0	(62.9-135.0)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.9	nc	(nc-nc)
Male	2	4.3	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.1	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	4.8	nc	(nc-nc)
Male	5	2.8	177.1	(57.1-413.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.0	nc	(nc-nc)	Female	11	6.2	177.1	(88.3-316.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.2	nc	(nc-nc)	Male	97	108.6	89.4	(72.5-109.0)
Female	0	0.7	nc	(nc-nc)	Female	93	96.9	95.9	(77.4-117.5)
<b><u>Lung and Bronchus</u></b>									
Male	17	14.6	116.6	(67.9-186.7)					
Female	10	13.5	74.2	(35.5-136.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	28	28.7	97.6	(64.8-141.1)	Male	21	19.5	107.6	(66.6-164.4)
Female	16	10.3	155.5	(88.8-252.5)	Female	12	15.3	78.3	(40.4-136.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	6.1	nc	(nc-nc)	Male	9	4.8	188.7	(86.1-358.2)
Female	5	4.9	103.1	(33.2-240.5)	Female	2	3.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	10	16.7	59.7	(28.6-109.9)
Female	108	113.5	95.1	(78.0-114.9)	Female	16	13.5	118.2	(67.5-192.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	4.9	122.5	(44.7-266.6)	Male	14	12.4	113.3	(61.9-190.0)
<b><u>Colon / Rectum</u></b>					Female	3	5.3	nc	(nc-nc)
Male	43	37.7	114.0	(82.5-153.6)	<b><u>Ovary</u></b>				
Female	32	34.3	93.4	(63.9-131.9)	Female	15	10.8	139.2	(77.8-229.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	8.0	99.8	(43.0-196.6)	Male	22	9.3	237.3	(148.7-359.3)
Female	1	2.0	nc	(nc-nc)	Female	16	9.0	177.0	(101.1-287.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	119	115.7	102.8	(85.2-123.0)
Female	2	2.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	7.0	71.4	(23.0-166.7)
Male	19	16.1	118.0	(71.0-184.3)	Female	5	3.8	133.0	(42.9-310.3)
Female	11	9.1	121.2	(60.4-217.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	4.4	nc	(nc-nc)
Male	4	4.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	5	6.3	79.5	(25.6-185.6)
<b><u>Leukemia</u></b>					Female	28	19.9	141.0	(93.7-203.8)
Male	10	10.5	95.3	(45.6-175.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	17	7.6	223.3	(130.0-357.6)	Female	32	25.8	123.9	(84.7-174.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	14	8.3	168.0	(91.8-282.0)	Male	433	403.5	107.3	(97.4-117.9)
Female	1	2.6	nc	(nc-nc)	Female	443	380.6	116.4	(105.8-127.7)
<b><u>Lung and Bronchus</u></b>									
Male	55	53.9	102.1	(76.9-132.9)					
Female	74	52.4	141.1	(110.8-177.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	4.9	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	Female	5	2.6	192.4	(62.0-449.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	2.6	191.1	(61.6-446.0)
Female	28	19.5	143.4	(95.2-207.2)	Female	0	2.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	0.7	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.0	nc	(nc-nc)
Male	7	6.1	113.9	(45.6-234.6)	<b><u>Ovary</u></b>				
Female	9	7.4	121.3	(55.4-230.3)	Female	3	1.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	0.4	nc	(nc-nc)	Male	22	17.2	127.6	(79.9-193.1)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.2	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.5	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	2.8	246.5	(98.8-507.9)
Male	2	1.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.5	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	73	63.1	115.8	(90.7-145.5)
Female	2	0.5	nc	(nc-nc)	Female	78	70.8	110.1	(87.0-137.4)
<b><u>Lung and Bronchus</u></b>									
Male	12	8.9	135.0	(69.7-235.9)					
Female	11	10.5	104.3	(52.0-186.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	8.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	5.1	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.2	nc	(nc-nc)					
Female	0	0.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	8.1	111.5	(50.9-211.7)	Male	9	5.0	181.0	(82.6-343.6)
Female	3	2.6	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.5	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
Female	35	27.0	129.6	(90.2-180.2)	Female	2	3.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.3	nc	(nc-nc)
Male	6	10.2	58.6	(21.4-127.7)	<b><u>Ovary</u></b>				
Female	14	8.9	157.8	(86.2-264.8)	Female	2	2.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	36	30.3	118.9	(83.3-164.6)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.9	nc	(nc-nc)
Male	3	4.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.8	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	4.2	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.9	nc	(nc-nc)	Female	8	6.0	132.4	(57.0-260.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	104	106.5	97.6	(79.8-118.3)
Female	0	0.7	nc	(nc-nc)	Female	94	92.4	101.7	(82.2-124.5)
<b><u>Lung and Bronchus</u></b>									
Male	9	14.9	60.5	(27.6-114.9)					
Female	9	13.2	68.1	(31.1-129.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	6.1	230.6	(126.0-387.0)	Male	7	4.8	144.6	(57.9-297.9)
Female	2	2.3	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.7	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	31	29.2	106.2	(72.2-150.8)	Female	3	3.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.3	nc	(nc-nc)
Male	9	8.7	103.2	(47.1-195.8)	<b><u>Ovary</u></b>				
Female	12	7.8	152.9	(78.9-267.1)	Female	3	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	21	26.3	79.9	(49.5-122.2)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.6	nc	(nc-nc)
Male	5	4.0	123.7	(39.9-288.7)	Female	0	0.9	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.4	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	5.8	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.9	nc	(nc-nc)	Female	4	6.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	106	94.2	112.5	(92.1-136.1)
Female	1	0.6	nc	(nc-nc)	Female	97	93.2	104.1	(84.4-127.0)
<b><u>Lung and Bronchus</u></b>									
Male	15	11.6	129.1	(72.2-213.0)					
Female	17	11.5	147.6	(85.9-236.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Truro

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	3.3	183.7	(67.1-399.9)	Male	0	1.9	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	15	11.1	135.2	(75.6-223.0)	Female	0	1.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	7	4.1	172.0	(68.9-354.4)	<b><u>Ovary</u></b>				
Female	2	3.6	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	17	11.7	145.6	(84.8-233.2)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.8	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.8	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.7	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	54	41.7	129.4	(97.2-168.8)
Female	0	0.3	nc	(nc-nc)	Female	35	37.8	92.7	(64.6-128.9)
<b><u>Lung and Bronchus</u></b>									
Male	4	5.9	nc	(nc-nc)					
Female	6	5.4	111.1	(40.6-241.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	7.4	107.4	(46.3-211.7)	Male	6	5.8	103.5	(37.8-225.3)
Female	5	2.6	189.4	(61.1-442.1)	Female	7	5.0	141.4	(56.6-291.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.0	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
Female	48	34.3	140.0	(103.2-185.6)	Female	5	3.8	132.9	(42.8-310.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.7	nc	(nc-nc)	Male	6	3.7	160.9	(58.8-350.2)
<b><u>Colon / Rectum</u></b>					Female	2	1.5	nc	(nc-nc)
Male	17	10.4	162.7	(94.7-260.6)	<b><u>Ovary</u></b>				
Female	7	9.2	76.2	(30.5-156.9)	Female	1	3.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	6	2.3	259.0	(94.6-563.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	28	30.7	91.2	(60.6-131.8)
Female	2	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.9	nc	(nc-nc)
Male	2	4.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.8	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	7.1	112.5	(48.4-221.7)
Male	2	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.3	nc	(nc-nc)	Female	5	7.4	67.8	(21.8-158.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	2.4	205.6	(66.3-479.8)	Male	119	112.4	105.9	(87.7-126.7)
Female	0	0.7	nc	(nc-nc)	Female	133	110.4	120.5	(100.9-142.8)
<b><u>Lung and Bronchus</u></b>									
Male	19	14.1	135.2	(81.3-211.1)					
Female	16	13.6	117.7	(67.2-191.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	12	7.8	154.7	(79.8-270.2)
Female	0	0.0	nc	(nc-nc)	Female	4	6.0	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	3	1.0	nc	(nc-nc)					
Female	0	0.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	5.0	180.7	(82.5-343.0)	Male	1	3.7	nc	(nc-nc)
Female	6	1.9	308.8	(112.8-672.2)	Female	2	3.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	24	22.0	109.0	(69.8-162.2)	Female	0	2.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.0	nc	(nc-nc)
Male	2	6.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	6.8	73.8	(23.8-172.3)	Female	3	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	5	1.7	287.8	(92.7-671.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	31	20.4	152.1	(103.3-215.9)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.3	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.0	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	4.2	190.0	(81.8-374.4)
Male	4	2.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	1.6	nc	(nc-nc)	Female	5	4.7	105.8	(34.1-246.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	86	73.1	117.7	(94.1-145.3)
Female	0	0.5	nc	(nc-nc)	Female	86	73.8	116.6	(93.2-144.0)
<b><u>Lung and Bronchus</u></b>									
Male	10	9.3	107.4	(51.4-197.5)					
Female	8	9.6	83.6	(36.0-164.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	9.5	169.0	(96.5-274.4)	Male	6	6.8	88.0	(32.1-191.6)
Female	10	3.8	261.2	(125.1-480.5)	Female	3	6.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.3	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.9	119.0	(47.7-245.3)
Female	44	41.7	105.6	(76.7-141.8)	Female	8	5.1	157.7	(67.9-310.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.0	nc	(nc-nc)	Male	5	4.3	117.5	(37.9-274.2)
<b><u>Colon / Rectum</u></b>					Female	1	2.0	nc	(nc-nc)
Male	15	12.7	118.4	(66.2-195.3)	<b><u>Ovary</u></b>				
Female	12	13.1	91.9	(47.4-160.5)	Female	5	4.0	126.3	(40.7-294.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	1.1	nc	(nc-nc)	Male	53	37.7	140.6	(105.3-183.9)
Female	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.3	nc	(nc-nc)
Male	5	5.6	90.0	(29.0-210.1)	Female	1	1.5	nc	(nc-nc)
Female	6	3.3	181.3	(66.2-394.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	2.0	306.9	(112.1-667.9)
Male	1	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	7.9	126.3	(60.5-232.2)
Male	4	3.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	3.0	167.1	(53.8-389.9)	Female	11	9.0	121.6	(60.6-217.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.8	nc	(nc-nc)	Male	174	136.2	127.8	(109.5-148.2)
Female	0	1.0	nc	(nc-nc)	Female	168	141.8	118.4	(101.2-137.8)
<b><u>Lung and Bronchus</u></b>									
Male	26	17.8	146.3	(95.6-214.4)					
Female	30	18.9	158.4	(106.9-226.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	28	28.6	97.9	(65.0-141.5)	Male	14	17.9	78.1	(42.7-131.1)
Female	11	11.6	95.0	(47.4-170.0)	Female	17	14.8	115.2	(67.1-184.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	5.5	109.5	(40.0-238.2)	Male	3	4.5	nc	(nc-nc)
Female	2	4.7	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	14	15.7	89.4	(48.8-150.0)
Female	129	108.4	119.0	(99.4-141.4)	Female	17	14.4	117.7	(68.5-188.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	4.4	nc	(nc-nc)	Male	8	10.8	73.9	(31.8-145.6)
<b><u>Colon / Rectum</u></b>					Female	3	5.4	nc	(nc-nc)
Male	30	36.0	83.2	(56.2-118.8)	<b><u>Ovary</u></b>				
Female	28	39.4	71.1	(47.3-102.8)	Female	13	10.6	122.7	(65.3-209.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	7.4	134.7	(64.5-247.7)	Male	5	9.0	55.8	(18.0-130.3)
Female	3	2.3	nc	(nc-nc)	Female	6	10.4	57.8	(21.1-125.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	96	103.9	92.4	(74.9-112.9)
Female	2	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	6.8	nc	(nc-nc)
Male	15	14.6	102.6	(57.4-169.2)	Female	5	4.5	111.7	(36.0-260.7)
Female	7	9.1	77.2	(30.9-159.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.7	nc	(nc-nc)
Male	5	4.2	118.1	(38.1-275.6)	<b><u>Thyroid</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	9	5.4	167.2	(76.3-317.4)
<b><u>Leukemia</u></b>					Female	16	17.2	93.1	(53.2-151.3)
Male	12	9.9	121.5	(62.7-212.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	8.1	123.4	(59.1-226.9)	Female	21	23.9	88.0	(54.5-134.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	7.5	93.6	(37.5-192.8)	Male	348	375.7	92.6	(83.1-102.9)
Female	2	2.8	nc	(nc-nc)	Female	388	386.0	100.5	(90.8-111.0)
<b><u>Lung and Bronchus</u></b>									
Male	42	52.2	80.4	(58.0-108.7)					
Female	53	55.5	95.5	(71.5-124.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	2	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	9	6.6	137.1	(62.5-260.2)	Female	0	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	4	2.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	1.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	6.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.3	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.3	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	22	22.1	99.7	(62.5-151.0)
Female	0	0.1	nc	(nc-nc)	Female	25	20.6	121.5	(78.6-179.4)
<b><u>Lung and Bronchus</u></b>									
Male	2	2.7	nc	(nc-nc)					
Female	5	2.5	196.7	(63.4-459.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;